Drug Price Trends for MENOPUR

Average Pharmacy Cost for MENOPUR

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
MENOPUR 75 UNIT VIAL	55566-7501-02	243.30844	EACH	2025-04-04

MENOPUR: Market Landscape and Price Trajectory Analysis

Last updated: February 19, 2026

This report analyzes the current market position and projects future price trends for MENOPUR, a gonadotropin medication primarily used in assisted reproductive technologies (ART). The analysis considers patent status, competition, regulatory factors, and market demand to inform R&D and investment decisions.

What is MENOPUR and its Therapeutic Role?

MENOPUR (menotropins for injection) is a prescription medication derived from the urine of postmenopausal women. It contains a combination of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are essential for ovulation induction in women undergoing fertility treatments. MENOPUR is indicated for the stimulation of follicular development in women who are infertile but have intact ovarian function. It is administered via subcutaneous or intramuscular injection.

The primary therapeutic use of MENOPUR is within the field of assisted reproductive technologies, including:

• Ovulation Induction: For women who do not ovulate naturally or have irregular ovulation cycles.
• Controlled Ovarian Stimulation: In conjunction with intrauterine insemination (IUI) or in vitro fertilization (IVF) cycles, to stimulate the development of multiple follicles.

MENOPUR's mechanism of action involves mimicking the natural release of FSH and LH, which are critical for the maturation of ovarian follicles and subsequent ovulation.

What is the Patent Status of MENOPUR?

MENOPUR's active pharmaceutical ingredient, menotropins, is a biological product derived from a natural source. As such, its patent landscape differs from that of small molecule drugs. The original patents related to the purification and production of menotropins have long expired. However, patents can exist for specific formulations, delivery devices, or novel manufacturing processes.

As of the latest available data, MENOPUR (brand name manufactured by Ferring Pharmaceuticals) does not appear to be protected by active composition of matter patents that would prevent generic competition of the core menotropins product. The key patent for the original U.S. formulation and use expired decades ago.

• US Patent 4,041,130: This patent, related to the purification of human gonadotropins, expired in 1997. [1]
• Other Formulation/Device Patents: While the core API is largely off-patent, manufacturers may hold patents on specific drug delivery systems or improved formulations that could offer some limited protection or competitive advantage until their expiration. For example, patents might cover pre-filled syringes or specific lyophilization techniques. The expiration dates for such patents would need to be individually assessed.

The absence of broad composition of matter patents on menotropins has facilitated the entry of biosimilar and generic versions of gonadotropins into the market.

Who are the Key Competitors for MENOPUR?

The fertility drug market, particularly for gonadotropins, is competitive. MENOPUR faces competition from both branded and generic versions of recombinant FSH (rFSH) and other menotropin preparations.

Major Competitors and Product Offerings:

• Gonal-f (follitropin alfa) - Merck KGaA/EMD Serono: A highly prevalent recombinant FSH (rFSH) used for similar indications. Gonal-f is a recombinant product, offering a more standardized and potentially higher purity profile compared to MENOPUR.
• Follistim (follitropin beta) - Organon (formerly MSD): Another widely used recombinant FSH product.
• Bravelle (urofollitropin) - Merck KGaA/EMD Serono: Urofollitropin is a purified FSH derived from urine, similar in origin to MENOPUR but typically lacking the LH component.
• Repronex (menotropins) - Generics (Various Manufacturers): Generic versions of menotropins are available, directly competing with branded MENOPUR. These products are often significantly lower in price.
• Elonva (corifollitropin alfa) - Organon: A long-acting recombinant FSH analog offering a single injection for follicular stimulation, representing a different approach to FSH administration.

Competition Dynamics:

• Recombinant vs. Urinary-Derived: rFSH products like Gonal-f and Follistim are often perceived as more advanced due to their recombinant nature, offering potentially higher purity and consistency. However, MENOPUR and Bravelle, being urine-derived, remain viable options, particularly when cost is a significant factor or when LH activity is desired.
• Branded vs. Generic: The availability of generic menotropins and rFSH has significantly pressured the pricing of branded products, including MENOPUR.
• Clinical Efficacy and Physician Preference: While efficacy profiles are broadly similar for these agents, physician experience, patient response, and specific treatment protocols can influence product selection.

What is the Current Market Size and Growth Rate for Gonadotropins?

The global market for gonadotropins is substantial and driven by increasing rates of infertility worldwide, delayed childbearing, and advancements in ART.

• Global Gonadotropin Market Value: The global gonadotropin market was estimated to be approximately USD 4.5 billion in 2022 and is projected to reach USD 7.0 billion by 2030, exhibiting a compound annual growth rate (CAGR) of around 5.5% during this period. [2]
• Market Drivers:
  • Rising Infertility Rates: Global infertility rates continue to rise due to factors such as lifestyle changes, environmental factors, and increased age of first-time mothers.
  • Technological Advancements in ART: Improvements in IVF and other ART procedures increase the demand for effective ovulation induction agents.
  • Increasing Awareness and Access: Greater awareness of fertility treatments and improved healthcare infrastructure in developing economies contribute to market expansion.
  • Government Initiatives and Reimbursement Policies: In some regions, government support and insurance coverage for fertility treatments boost market growth.
• MENOPUR's Market Share: While specific market share data for MENOPUR is proprietary, it is considered a significant player among urine-derived gonadotropins, competing directly with other menotropin products and indirectly with rFSH. The overall market for menotropins is smaller than that for rFSH, reflecting the trend towards recombinant products.

What are the Pricing Trends and Projections for MENOPUR?

The pricing of MENOPUR is influenced by several factors, including manufacturing costs, competitive landscape, payer negotiations, and the availability of generic alternatives.

Historical and Current Pricing:

MENOPUR's price has historically been subject to fluctuations. As a branded pharmaceutical, it commands a premium over generic alternatives.

• Branded MENOPUR: A typical course of treatment with branded MENOPUR can range from $2,500 to $7,000 or more, depending on the dosage, duration of treatment, and geographic location. This cost is often covered partially or fully by insurance, but co-pays can still be substantial.
• Generic MENOPUR/Menotropins: Generic versions of menotropins are available and can significantly undercut the price of branded MENOPUR, often costing 30% to 50% less. This price differential is a primary driver for the adoption of generics.
• Comparison with rFSH: Branded rFSH products like Gonal-f are generally priced in a similar range to branded MENOPUR, sometimes slightly higher, depending on the specific product and delivery system.

Price Projections:

The future pricing of MENOPUR will likely be characterized by continued pressure from generics and a stabilizing demand from its established therapeutic niche.

• Downward Pressure from Generics: The presence of affordable generic menotropin options will continue to limit the pricing power of branded MENOPUR. Ferring Pharmaceuticals may offer discount programs or tiered pricing to maintain market share.
• Market Stability for Niche Indications: For specific patient populations or where LH activity is deemed critical by clinicians, MENOPUR will likely retain its demand. This stable demand in a defined segment can support a certain price point, albeit not one that can drastically increase.
• Competition from Biosimil rFSH: As biosimil versions of recombinant FSH enter the market (though less common for human gonadotropins than for monoclonal antibodies), they could further erode the market share of both branded MENOPUR and branded rFSH, potentially impacting overall pricing dynamics.
• Payer Influence: Insurance companies and national health systems play a critical role in negotiating drug prices. Their preference for cost-effective treatments, including generics, will continue to influence MENOPUR's net price.

Projected Price Trajectory:

• Short-Term (1-3 years): Expect marginal price increases for branded MENOPUR, primarily to keep pace with inflation and R&D reinvestment. However, the overall realized price will likely be depressed by generic competition and payer negotiations.
• Medium-Term (3-7 years): Prices for branded MENOPUR are likely to remain relatively stable or experience slight declines in real terms, as generic penetration solidifies. The market share will likely stabilize within its established therapeutic context.
• Long-Term (7+ years): Without significant product differentiation or new therapeutic indications, the pricing power of branded MENOPUR will be minimal. The market will largely be driven by generic competition and the overall cost-effectiveness of ART treatments.

Key Price Influencers Summary:

• Generic Competition: Primary driver for price suppression.
• Payer Negotiations: Significant impact on net prices.
• Manufacturing Costs: Influence on the floor price.
• Clinical Utility: Demand in specific patient populations.
• Advancements in ART: Continued demand for ovulation induction agents.

What are the Regulatory and Reimbursement Landscapes?

The regulatory and reimbursement landscapes significantly impact the market access and profitability of MENOPUR.

Regulatory Status:

MENOPUR is approved by major regulatory bodies worldwide, including:

• U.S. Food and Drug Administration (FDA): Approved for ovulation induction.
• European Medicines Agency (EMA): Approved for similar indications across EU member states.
• Other National Regulatory Authorities: Approved in Canada, Australia, Japan, and many other countries.

The regulatory pathway for menotropins is well-established. Manufacturers must adhere to Good Manufacturing Practices (GMP) and submit post-market surveillance data. The regulatory environment for fertility drugs is generally stable, although evolving guidelines on ART can indirectly influence demand.

Reimbursement Landscape:

Reimbursement for fertility treatments, including MENOPUR, varies significantly by country and by insurance provider within countries.

• United States: Reimbursement is highly fragmented. Some employers offer comprehensive fertility benefits, while others provide limited coverage or none at all. The high cost of ART treatments often leads to significant out-of-pocket expenses for patients. Payer formularies and prior authorization requirements can influence which gonadotropins are preferred.
• Europe: Many European countries have public healthcare systems that offer some level of funding for fertility treatments, often with limitations on the number of cycles or age of the patients. However, coverage varies widely, and out-of-pocket costs remain common.
• Other Regions: Reimbursement policies are diverse, ranging from comprehensive coverage in some Middle Eastern countries to limited public funding in many Asian nations.

Impact on MENOPUR:

• Payer Prioritization: Payers often favor lower-cost generic options when clinical outcomes are comparable. This pressures branded MENOPUR.
• Formulary Access: Inclusion on payer formularies, often with preferred status for generics, dictates market access.
• Patient Affordability: High out-of-pocket costs can lead patients to opt for cheaper alternatives if clinically appropriate.
• Advocacy and Policy Changes: Patient advocacy groups and policy changes aimed at increasing access to fertility treatments can positively impact demand for all gonadotropins.

What are the Key Risks and Opportunities?

Analyzing the risks and opportunities associated with MENOPUR is crucial for strategic planning.

Key Risks:

• Intensifying Generic Competition: The most significant risk is the continued growth and aggressive pricing of generic menotropins and potentially biosimilar rFSH.
• Shift Towards Recombinant FSH: A growing preference among clinicians and patients for rFSH products due to perceived standardization and purity.
• Reimbursement Restrictions: Further tightening of payer coverage for fertility treatments or limitations on the use of specific drug classes.
• Adverse Event Scrutiny: As a urine-derived product, MENOPUR may face ongoing scrutiny regarding potential viral transmission or immunogenicity, although robust screening processes are in place.
• Emergence of Novel Therapies: Development of entirely new approaches to ovulation induction or ovarian stimulation that bypass the need for traditional gonadotropins.

Key Opportunities:

• Emerging Markets: Growing demand for ART in developing economies where cost-effectiveness may favor urine-derived gonadotropins like MENOPUR.
• Combination Therapies: Potential for MENOPUR to be included in novel combination therapies or treatment protocols that enhance ART success rates.
• Differentiated Formulations/Delivery Systems: While the core API is off-patent, developing innovative delivery devices or formulations that improve patient convenience or efficacy could offer a competitive edge, though patent protection for such innovations would be critical.
• Targeted Patient Populations: Identifying specific sub-groups of patients who respond optimally to menotropins (with both FSH and LH activity) and marketing MENOPUR for these niche indications.
• Partnerships and Strategic Alliances: Collaborations with ART clinics or other pharmaceutical companies to expand market reach and co-promote treatments.

Key Takeaways

MENOPUR operates in a competitive and mature market for gonadotropins, primarily driven by assisted reproductive technologies. Its patent protection has expired for the active pharmaceutical ingredient, leading to significant competition from generic menotropins and recombinant FSH (rFSH) products.

Market growth is underpinned by rising infertility rates and advancements in ART. However, pricing is under constant downward pressure due to generics and payer negotiations. While branded MENOPUR maintains a presence, particularly where LH activity is desired, its market share and pricing power are constrained.

The future trajectory of MENOPUR will likely involve stable but challenged market positioning, with opportunities lying in emerging markets and potentially in niche therapeutic applications. Significant price increases are unlikely.

Frequently Asked Questions

1. What is the primary difference between MENOPUR and recombinant FSH (rFSH) products like Gonal-f? MENOPUR is a mixture of FSH and LH derived from the urine of postmenopausal women, while rFSH products are manufactured using recombinant DNA technology and contain only FSH.
2. How does the availability of generic MENOPUR impact the price of the branded product? The availability of generic menotropins significantly reduces the pricing power of branded MENOPUR, often leading to price discounts or lower realized net prices for the branded version.
3. Are there any new therapeutic indications being explored for MENOPUR? Current research and development primarily focus on optimizing ART protocols rather than novel indications for MENOPUR itself, given its established therapeutic profile.
4. What is the typical duration of MENOPUR treatment for a patient undergoing IVF? The duration of MENOPUR treatment varies based on individual patient response and the specific ART protocol, but typically ranges from 7 to 14 days of stimulation before egg retrieval.
5. Can MENOPUR be used in male fertility treatments? MENOPUR is primarily indicated for ovulation induction in women. Gonadotropins are also used in male fertility treatments, but specific formulations and dosages may differ, and MENOPUR's labeling is for female use.

Citations

[1] U.S. Patent 4,041,130. (1977). Purification of human gonadotropins. Retrieved from USPTO database. [2] Grand View Research. (2023). Gonadotropin Market Size, Share & Trends Analysis Report By Product Type (FSH, LH, hCG), By Source (Urine, Recombinant), By Application (Ovulation Induction, Male Infertility), By End-use (Hospitals, Fertility Clinics), By Region, And Segment Forecasts, 2024 – 2030. Retrieved from Grand View Research website.